Is the Neulasta Market Poised for Significant Growth? The Neulasta market has experienced considerable expansion in recent years, with a strong historic compound annual growth rate (HCAGR). .The ...

One such instance was in December 2023, Coherus BioSciences, a US-based biopharmaceutical company, which announced that the U.S. FDA had approved UDENYCA ONBODY, a new on-body injector for ...

Kochi: Producer Antony Perumbavoor has withdrawn his controversial Facebook post targeting G Suresh Kumar, Vice President of the Producers Association. The post, which criticised Suresh Kumar, has ...

Piscataway, N.J., United States: Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection ...

Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other ...

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim ...

PISCATAWAY, N.J. — Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial ...

Hema Malini and Amitabh Bachchan’s on-screen pairing in films like Baghban was well-received, with Jaya Bachchan dismissing any jealousy, appreciating Hema’s performance. Dharmendra avoided ...

In a recent interview, Paresh Rawal defended his Hera Pheri co-star Akshay Kumar against criticism of doing ‘too many films’ and said this. Akshay Kumar and Paresh Rawal have worked together ...

Speaking at the launch of Namma Raste, he said resolving the city's congestion issues would take at least three years. Bengaluru’s traffic woes are so severe that even divine intervention wouldn ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...